Ontario Genomics

Aima Laboratories is a women's health healthcare company that provides innovative solutions to diagnostic and therapeutic difficulties. AIMA is working on the first non-invasive endometriosis diagnostic tool for the market. If you have chronic pelvic/period pain or are having difficulty becoming pregnant, you may have endometriosis.

Genecis is an early-stage organic waste processing startup that uses biotechnology to convert waste into biodegradable plastics and other high-value materials. It converts organic waste into PHA (Polyhydroxyalkanoate), a biodegradable, compostable, and non-toxic polymer that can be tuned to replace a wide variety of traditional plastics. PHA can be used for single-use plastics, clothing and textiles, automotive interiors, medical tools and products, and food contact applications.

Liven creates plant-based foods' maximum potential in terms of flavor, texture, and cooking experience by creating animal-free protein ingredients. The company generates protein ingredients to meet functional requirements for plant-based food formulations, such as the ideal gelling strength, anticipated property changes during cooking, and desired emulsification properties. Liven's goal is to make the food industry more sustainable by enabling the circular economy.

Ceragen is a biotechnology company that helps farmers increase crop yields through plant microbiome engineering. It develops precision microbiome engineering via inoculant products tailored for controlled environment agriculture, enabling crops to respond to environmental stress and to produce more in limited space with an all-natural solution. Ceragen was established in Kitchener, Ontario.

Index Biosystems specializes in genetic traceability solutions for the food system. Its core technology involves inserting inert genetic constructs into products, enabling accurate identification within hours, even in co-mingled or transformed states. This enhances recall efficiency and expands traceability from seed to waste.

Biofect Innovations develops microorganisms using synthetic biology and fermentation technology to produce sustainable, nature-like ingredients for food products. Their mission is to create economical and environmentally responsible food items that enhance future generations' environment.

Kraken Sense develops an automated pathogen detection platform that uses cutting-edge nanotechnology and IoT-enabled dashboard for real-time bacterial contamination monitoring.

Ardra Inc. is a renewable chemicals company based in Toronto, Canada, specializing in the production of petroleum-free specialty chemicals for the personal care and cosmetics industry. Utilizing technology developed at the University of Toronto, Ardra employs model-guided metabolic engineering and synthetic biology to create biocatalysts that convert renewable resources into essential chemicals. The company's flagship product is 1,3-butanediol, a sustainable alternative to petroleum-based counterparts, which is utilized in various applications including cosmetics, food, polymers, and pharmaceuticals. With the cosmetics sector relying heavily on petroleum chemicals, valued at approximately $2.6 billion, Ardra aims to provide environmentally friendly solutions that stabilize and sustain the supply chain while reducing ecological impact.

Tissue Regeneration Therapeutics Inc. is a biotechnology company based in Toronto, Canada, specializing in the development of advanced cell therapy products derived from Human Umbilical Cord PeriVascular Cells (HUCPVC). Founded in 2004, the company has identified a rich source of mesenchymal stromal/stem cells (MSCs) known for their regenerative, angiogenic, anti-inflammatory, and immuno-regulatory properties, which distinguishes its technology from other tissue sources. In addition to its HUCPVC platform, Tissue Regeneration Therapeutics is developing OsteoScaf, a biodegradable scaffold designed to facilitate the healing of tissue defects. The company's strategic alliance with RoosterBio Inc. enhances its capabilities in the commercialization of its innovative therapies, supporting clinical research across various medical indications.

InDanio Bioscience Inc. is a privately-held drug discovery company based in Toronto, Canada, specializing in the development of new chemical entities targeting nuclear receptor protein families. Established in 2008, the company utilizes a proprietary Ligand Trap system featuring 48 transgenic zebrafish lines, each expressing one of the human nuclear receptors, to facilitate the simultaneous evaluation of drug delivery, stability, specificity, tissue selectivity, and toxicity. This innovative approach enables the identification, extraction, and characterization of new hormonal regulators, as well as the discovery of tissue-selective drugs and their associated mechanisms of action. Through its advanced screening techniques, InDanio Bioscience aims to enhance the drug development process and contribute to the advancement of therapeutic options in the pharmaceutical industry.